Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14900332 | 0.92 | RAB9A (0.62) | PPARGEPHX2SMN1; SMN2MEN1RAB9A | |
| SCHEMBL6077802 | 0.87 | L3MBTL1 (0.77) | LMNAPPARGEPHX2L3MBTL1SMN1; SMN2 | |
| SCHEMBL10099559 | 0.85 | SMN1; SMN2 (0.76) | LMNAPPARGEPHX2L3MBTL1HPGD | |
| SCHEMBL104476 | 0.85 | SMN1; SMN2 (0.76) | LMNAPPARGEPHX2L3MBTL1HPGD | |
| SCHEMBL23894858 | 0.84 | HDAC1 (0.65) | LMNAPPARGEPHX2RAB9APOLB | |
| SCHEMBL6357065 | 0.83 | LMNA (0.70) | LMNAPPARGEPHX2L3MBTL1HPGD | |
| SCHEMBL8429875 | 0.83 | LMNA (0.70) | LMNAPPARGEPHX2L3MBTL1SMN1; SMN2 | |
| SCHEMBL10099594 | 0.83 | LMNA (0.70) | LMNAPPARGEPHX2L3MBTL1HPGD | |
| SCHEMBL28662967 | 0.82 | PPARG (0.81) | LMNAPPARGEPHX2PPARA | |
| SCHEMBL20715712 | 0.82 | PTPN1 (0.61) | LMNAHPGDSMN1; SMN2MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | LMNA 1907/4885PPARG 2808/4885EPHX2 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.